Transave Completes Successful Phase II Clinical Program For ARIKACE In The Treatment Of Pseudomonas Lung Infections
Transave Inc., reported additional positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections.
(more...)
(more...)